{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:17Z","timestamp":1787841317682,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic Idiopathic Urticaria (CIU) is a debilitating disease characterised by almost daily presence of urticarial symptoms like short-lived wheals, itching, and erythema for at least 6 weeks without an identifiable cause there by leading to impairment of quality of life of the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of loratadine and rupatadine in chronic idiopathic urticaria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a prospective, randomized, single-blind, parallel arm study conducted to evaluate the efficacy and safety of loratadine and rupatadine in patients with CIU. The study was registered prospectively with Clinical Trial registry of India (CTRI\/2017\/05\/008624). Institutional Ethics Committee clearance was obtained. Written informed consent was obtained from all the participants before enrolment into the trial. The study was conducted in the outpatient department of Dermatology, SRM Medical College, Kattankulathur, Tamil Nadu, India, during the period from June 2017 to August 2018. Patients with CIU enrolled into the study based on inclusion-exclusion criteria were given the intervention drugs; Loratadine 10 mg once daily or rupatadine10 mg once daily orally for 6 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Rupatadine is more efficacious than loratadine in the reduction of Total Leucocyte Count, Differential Count and Absolute Eosinophil Count, the key determinants of allergy. Rupatadine also produced better improvement in Total symptom Score, Dermatology Life Quality Index in patients with CIU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Analysis of all the parameters of efficacy and safety establishes the probable superiority of rupatadine over loratadine for the treatment of urticaria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_1042_20","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T03:01:56Z","timestamp":1649818916000},"page":"704-704","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Loratadine vs Rupatadine: Unearthing the Capital Choice in Chronic Idiopathic Urticaria (CIU) \u2013 A Randomized Controlled Trial"],"prefix":"10.4103","volume":"66","author":[{"given":"Syed H","family":"Fayaz","sequence":"first","affiliation":[{"name":"From the Novo Nordisk India Pvt Ltd, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathyanarayanan","family":"Varadarajan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SRM IST, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanofer","family":"Ansari","sequence":"additional","affiliation":[{"name":"Resident Medical Officer, Vijay Poly Clinic, Kumbakonam, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerin","family":"James","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SRM IST, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/ijd.IJD_308_17","article-title":"Consensus statement for the diagnosis and treatment of urticaria: A 2017 update","volume":"63","author":"Godse","year":"2018","journal-title":"Indian J Dermatol"},{"key":"R5-20250921","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2133.2005.06976.x","article-title":"Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity","volume":"154","author":"Staubach","year":"2006","journal-title":"Br J Dermatol"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0091-6749(99)70506-3","article-title":"Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria","volume":"103","author":"Hermes","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/1523-1747.ep12338544","article-title":"Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria","volume":"106","author":"Niimi","year":"1996","journal-title":"J Invest Dermatol"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/cea.12494","article-title":"BSACI guideline for the management of chronic urticaria and angioedema","volume":"45","author":"Powell","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/0019-5154.57603","article-title":"Chronic urticaria and treatment options","volume":"54","author":"Godse","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40629-014-0011-7","article-title":"Rupatadine: Efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects","volume":"23","author":"Shamizadeh","year":"2014","journal-title":"Allergo J Int"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.alit.2018.06.002","article-title":"Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial","volume":"68","author":"Hide","year":"2019","journal-title":"Allergol Int"},{"key":"R14-20250921","first-page":"334","article-title":"Wyniki leczenia loratadyna chorych na przewlek\u0142a pokrzywke [Results of treatment with loratadine in patients with chronic urticaria]","volume":"49","author":"Siergiejko","year":"1994","journal-title":"Pol Tyg Lek"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0149-2918(97)80112-9","article-title":"Loratadine in the treatment of urticaria","volume":"19","author":"Monroe","year":"1997","journal-title":"Clin Ther"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13555-015-0089-y","article-title":"Rupatadine in established treatment schemes improves chronic spontaneous urticaria symptoms and patients' quality of life: A prospective, non-interventional trial","volume":"5","author":"Metz","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1398-9995.2007.01330.x","article-title":"Rupatadine in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled multicentre study","volume":"62","author":"Gimenez-Arnau","year":"2007","journal-title":"Allergy"},{"issue":"Suppl 87","key":"R18-20250921","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1398-9995.2008.01640.x","article-title":"Rupatadine in allergic rhinitis and chronic urticaria","volume":"63","author":"Mullol","year":"2008","journal-title":"Allergy"},{"key":"R19-20250921","first-page":"34","article-title":"A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis","volume":"14","author":"Saint-Martin","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R20-20250921","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(24)36413-4","article-title":"Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)","volume":"280","author":"Merlos","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R21-20250921","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/pai.12460","article-title":"Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years","volume":"27","author":"Potter","year":"2016","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1042_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:44Z","timestamp":1787838584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1042_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_1042_20","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2020-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}